{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:33:06Z","timestamp":1790771586727,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T00:00:00Z","timestamp":1664323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T00:00:00Z","timestamp":1664323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Moffitt Foundation"},{"DOI":"10.13039\/501100004586","name":"Funda\u00e7\u00e3o Carlos Chagas Filho de Amparo \u00e0 Pesquisa do Estado do Rio de Janeiro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004930","name":"Funda\u00e7\u00e3o do C\u00e2ncer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004930","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:italic>BRCA1<\/jats:italic> (Breast Cancer 1, early onset) is linked to breast and ovarian cancer predisposition. Still, the risks conferred by a significant portion of <jats:italic>BRCA1<\/jats:italic> variants identified in the population remains unknown. Most of these variants of uncertain significance are missense alterations. However, the functional implications of small in-frame deletions and\/or insertions (indels) are also difficult to predict. Our group has previously evaluated the functional impact of 347 missense variants using an extensively validated transcriptional activity assay. Here we show a systematic assessment of 30 naturally occurring in-frame indels located at the C-terminal region of BRCA1. We identified positions sensitive and tolerant to alterations, expanding the knowledge of structural determinants of BRCA1 function. We further designed and assessed the impact of four single codon deletions in the tBRCT linker region and six nonsense variants at the C-terminus end of BRCA1. Amino acid substitutions, deletions or insertions in the disordered region do not significantly impact activity and are not likely to constitute pathogenic alleles. On the other hand, a sizeable fraction of in-frame indels at the BRCT domain significantly impact function. We then use a Bayesian integrative statistical model to derive the probability of pathogenicity for each variant. Our data highlights the importance of assessing the impact of small in-frame indels in <jats:italic>BRCA1<\/jats:italic> to improve risk assessment and clinical decisions for carriers.<\/jats:p>","DOI":"10.1038\/s41598-022-20500-4","type":"journal-article","created":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T13:05:19Z","timestamp":1664370319000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Assessment of small in-frame indels and C-terminal nonsense variants of BRCA1 using a validated functional assay"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1171-1030","authenticated-orcid":false,"given":"Thales C.","family":"Nepomuceno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0067-9805","authenticated-orcid":false,"given":"Ana P. P.","family":"dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4130-8215","authenticated-orcid":false,"given":"Vanessa C.","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0193-7738","authenticated-orcid":false,"given":"Anna B. R.","family":"Elias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7669-3980","authenticated-orcid":false,"given":"Thiago T.","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1115-8319","authenticated-orcid":false,"given":"Guilherme","family":"Suarez-Kurtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0066-2763","authenticated-orcid":false,"suffix":"Jr.","given":"Edwin S.","family":"Iversen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9417-9985","authenticated-orcid":false,"given":"Fergus J.","family":"Couch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8448-4801","authenticated-orcid":false,"given":"Alvaro N. A.","family":"Monteiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7053-0053","authenticated-orcid":false,"given":"Marcelo A.","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,28]]},"reference":[{"key":"20500_CR1","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nrc.2015.21","volume":"16","author":"CJ Lord","year":"2016","unstructured":"Lord, C. J. & Ashworth, A. BRCAness revisited. Nat. Rev. Cancer 16, 110\u2013120. https:\/\/doi.org\/10.1038\/nrc.2015.21 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"20500_CR2","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1016\/j.celrep.2016.11.063","volume":"17","author":"OJP Kyrieleis","year":"2016","unstructured":"Kyrieleis, O. J. P. et al. Three-Dimensional Architecture of the Human BRCA1-A Histone Deubiquitinase Core Complex. Cell Rep. 17, 3099\u20133106. https:\/\/doi.org\/10.1016\/j.celrep.2016.11.063 (2016).","journal-title":"Cell Rep."},{"key":"20500_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1073\/pnas.2021963118","volume":"118","author":"DR Whelan","year":"2021","unstructured":"Whelan, D. R. & Rothenberg, E. Super-resolution mapping of cellular double-strand break resection complexes during homologous recombination. Proc. Natl. Acad. Sci. USA 118, 1. https:\/\/doi.org\/10.1073\/pnas.2021963118 (2021).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"20500_CR4","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3389\/fmolb.2019.00079","volume":"6","author":"RM Densham","year":"2019","unstructured":"Densham, R. M. & Morris, J. R. Moving mountains-The BRCA1 promotion of DNA resection. Front. Mol. Biosci. 6, 79. https:\/\/doi.org\/10.3389\/fmolb.2019.00079 (2019).","journal-title":"Front. Mol. Biosci."},{"key":"20500_CR5","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/s41580-020-0218-z","volume":"21","author":"M Tarsounas","year":"2020","unstructured":"Tarsounas, M. & Sung, P. The antitumorigenic roles of BRCA1-BARD1 in DNA repair and replication. Nat. Rev. Mol. Cell Biol. 21, 284\u2013299. https:\/\/doi.org\/10.1038\/s41580-020-0218-z (2020).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"20500_CR6","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.molcel.2015.01.011","volume":"57","author":"E Hatchi","year":"2015","unstructured":"Hatchi, E. et al. BRCA1 recruitment to transcriptional pause sites is required for R-loop-driven DNA damage repair. Mol. Cell 57, 636\u2013647. https:\/\/doi.org\/10.1016\/j.molcel.2015.01.011 (2015).","journal-title":"Mol. Cell"},{"key":"20500_CR7","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1111\/cas.14859","volume":"112","author":"Y Yoshino","year":"2021","unstructured":"Yoshino, Y., Fang, Z., Qi, H., Kobayashi, A. & Chiba, N. Dysregulation of the centrosome induced by BRCA1 deficiency contributes to tissue-specific carcinogenesis. Cancer Sci 112, 1679\u20131687. https:\/\/doi.org\/10.1111\/cas.14859 (2021).","journal-title":"Cancer Sci"},{"key":"20500_CR8","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s10147-017-1182-2","volume":"23","author":"M Takaoka","year":"2018","unstructured":"Takaoka, M. & Miki, Y. BRCA1 gene: Function and deficiency. Int J Clin Oncol 23, 36\u201344. https:\/\/doi.org\/10.1007\/s10147-017-1182-2 (2018).","journal-title":"Int J Clin Oncol"},{"key":"20500_CR9","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1002\/embj.201385567","volume":"33","author":"A Gardini","year":"2014","unstructured":"Gardini, A., Baillat, D., Cesaroni, M. & Shiekhattar, R. Genome-wide analysis reveals a role for BRCA1 and PALB2 in transcriptional co-activation. EMBO J. 33, 890\u2013905. https:\/\/doi.org\/10.1002\/embj.201385567 (2014).","journal-title":"EMBO J."},{"key":"20500_CR10","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ejca.2020.12.023","volume":"146","author":"P Pujol","year":"2021","unstructured":"Pujol, P. et al. Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. Eur. J. Cancer 146, 30\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2020.12.023 (2021).","journal-title":"Eur. J. Cancer"},{"key":"20500_CR11","doi-asserted-by":"publisher","first-page":"4601","DOI":"10.1158\/0008-5472.CAN-20-1830","volume":"80","author":"JJ Krais","year":"2020","unstructured":"Krais, J. J. & Johnson, N. BRCA1 mutations in cancer: Coordinating deficiencies in homologous recombination with tumorigenesis. Can. Res. 80, 4601\u20134609. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-1830 (2020).","journal-title":"Can. Res."},{"key":"20500_CR12","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker, K. B. et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317, 2402\u20132416. https:\/\/doi.org\/10.1001\/jama.2017.7112 (2017).","journal-title":"JAMA"},{"key":"20500_CR13","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41416-018-0127-5","volume":"119","author":"NM Tung","year":"2018","unstructured":"Tung, N. M. & Garber, J. E. BRCA1\/2 testing: Therapeutic implications for breast cancer management. Br. J. Cancer 119, 141\u2013152. https:\/\/doi.org\/10.1038\/s41416-018-0127-5 (2018).","journal-title":"Br. J. Cancer"},{"issue":"Suppl 1","key":"20500_CR14","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1038\/ejhg.2016.95","volume":"24","author":"N Hoogerbrugge","year":"2016","unstructured":"Hoogerbrugge, N. & Jongmans, M. C. Finding all BRCA pathogenic mutation carriers: Best practice models. Eur J Hum Genet 24(Suppl 1), S19-26. https:\/\/doi.org\/10.1038\/ejhg.2016.95 (2016).","journal-title":"Eur J Hum Genet"},{"key":"20500_CR15","doi-asserted-by":"publisher","first-page":"522","DOI":"10.3390\/cancers11040522","volume":"11","author":"VA Golubeva","year":"2019","unstructured":"Golubeva, V. A., Nepomuceno, T. C. & Monteiro, A. N. A. Germline missense variants in BRCA1: New trends and challenges for clinical annotation. Cancers (Basel) 11, 522. https:\/\/doi.org\/10.3390\/cancers11040522 (2019).","journal-title":"Cancers (Basel)"},{"key":"20500_CR16","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1093\/annonc\/mdv278","volume":"26","author":"DM Eccles","year":"2015","unstructured":"Eccles, D. M. et al. BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance. Ann Oncol 26, 2057\u20132065. https:\/\/doi.org\/10.1093\/annonc\/mdv278 (2015).","journal-title":"Ann Oncol"},{"key":"20500_CR17","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1136\/jmedgenet-2019-106368","volume":"57","author":"AN Monteiro","year":"2020","unstructured":"Monteiro, A. N. et al. Variants of uncertain clinical significance in hereditary breast and ovarian cancer genes: best practices in functional analysis for clinical annotation. J. Med. Genet. 57, 509\u2013518. https:\/\/doi.org\/10.1136\/jmedgenet-2019-106368 (2020).","journal-title":"J. Med. Genet."},{"key":"20500_CR18","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/humu.23818","volume":"40","author":"MT Parsons","year":"2019","unstructured":"Parsons, M. T. et al. Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification. Hum. Mutat. 40, 1557\u20131578. https:\/\/doi.org\/10.1002\/humu.23818 (2019).","journal-title":"Hum. Mutat."},{"key":"20500_CR19","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1002\/humu.20897","volume":"29","author":"DE Goldgar","year":"2008","unstructured":"Goldgar, D. E. et al. Genetic evidence and integration of various data sources for classifying uncertain variants into a single model. Hum. Mutat. 29, 1265\u20131272. https:\/\/doi.org\/10.1002\/humu.20897 (2008).","journal-title":"Hum. Mutat."},{"key":"20500_CR20","first-page":"873","volume":"81","author":"DF Easton","year":"2007","unstructured":"Easton, D. F. et al. A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am.J Hum. Genet. 81, 873\u2013883 (2007).","journal-title":"Genet."},{"key":"20500_CR21","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41436-020-00991-0","volume":"23","author":"PCM Lyra Jr","year":"2021","unstructured":"Lyra, P. C. M. Jr. et al. Integration of functional assay data results provides strong evidence for classification of hundreds of BRCA1 variants of uncertain significance. Genet. Med. 23, 306\u2013315. https:\/\/doi.org\/10.1038\/s41436-020-00991-0 (2021).","journal-title":"Genet. Med."},{"key":"20500_CR22","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1136\/jmedgenet-2017-104707","volume":"54","author":"AE Toland","year":"2017","unstructured":"Toland, A. E. & Andreassen, P. R. DNA repair-related functional assays for the classification of BRCA1 and BRCA2 variants: A critical review and needs assessment. J. Med. Genet. 54, 721\u2013731. https:\/\/doi.org\/10.1136\/jmedgenet-2017-104707 (2017).","journal-title":"J. Med. Genet."},{"key":"20500_CR23","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.ajhg.2018.07.016","volume":"103","author":"LM Starita","year":"2018","unstructured":"Starita, L. M. et al. A multiplex homology-directed DNA repair assay reveals the impact of more than 1,000 BRCA1 missense substitution variants on protein function. Am. J. Hum. Genet. 103, 498\u2013508. https:\/\/doi.org\/10.1016\/j.ajhg.2018.07.016 (2018).","journal-title":"Am. J. Hum. Genet."},{"key":"20500_CR24","doi-asserted-by":"publisher","first-page":"3666","DOI":"10.1093\/hmg\/ddu075","volume":"23","author":"M Colombo","year":"2014","unstructured":"Colombo, M. et al. Comprehensive annotation of splice junctions supports pervasive alternative splicing at the BRCA1 locus: a report from the ENIGMA consortium. Hum. Mol. Genet. 23, 3666\u20133680. https:\/\/doi.org\/10.1093\/hmg\/ddu075 (2014).","journal-title":"Hum. Mol. Genet."},{"key":"20500_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1007752","volume":"14","author":"MS Cline","year":"2018","unstructured":"Cline, M. S. et al. BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2. PLoS Genet. 14, e1007752. https:\/\/doi.org\/10.1371\/journal.pgen.1007752 (2018).","journal-title":"PLoS Genet."},{"key":"20500_CR26","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1158\/0008-5472.CAN-06-3297","volume":"67","author":"MA Carvalho","year":"2007","unstructured":"Carvalho, M. A. et al. Determination of cancer risk associated with Germ Line BRCA1 missense variants by functional analysis. Can. Res. 67, 1494\u20131501 (2007).","journal-title":"Can. Res."},{"key":"20500_CR27","doi-asserted-by":"publisher","first-page":"5980","DOI":"10.1074\/jbc.RA118.005274","volume":"294","author":"VC Fernandes","year":"2019","unstructured":"Fernandes, V. C. et al. Impact of amino acid substitutions at secondary structures in the BRCT domains of the tumor suppressor BRCA1: Implications for clinical annotation. J. Biol. Chem. 294, 5980\u20135992. https:\/\/doi.org\/10.1074\/jbc.RA118.005274 (2019).","journal-title":"J. Biol. Chem."},{"key":"20500_CR28","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1158\/1055-9965.epi-10-1214","volume":"20","author":"ES Iversen","year":"2011","unstructured":"Iversen, E. S., Couch, F. J., Goldgar, D. E., Tavtigian, S. V. & Monteiro, A. N. A. A computational method to classify variants of uncertain significance using functional assay data with application to BRCA1. Cancer Epidemiol. Biomark. Prev. 20, 1078\u20131088. https:\/\/doi.org\/10.1158\/1055-9965.epi-10-1214 (2011).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"20500_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/npjgenmed.2016.1","volume":"1","author":"NT Woods","year":"2016","unstructured":"Woods, N. T. et al. Functional assays provide a robust tool for the clinical annotation of genetic variants of uncertain significance. NPJ Genom. Med. 1, 1. https:\/\/doi.org\/10.1038\/npjgenmed.2016.1 (2016).","journal-title":"NPJ Genom. Med."},{"key":"20500_CR30","doi-asserted-by":"publisher","first-page":"16001","DOI":"10.1038\/npjgenmed.2016.1","volume":"1","author":"NTBR Woods","year":"2016","unstructured":"Woods, N. T. B. R. et al. Functional assays provide a robust tool for the clinical annotation of genetic variants of uncertain significance. NPJ Genom. Med. 1, 16001 (2016).","journal-title":"NPJ Genom. Med."},{"key":"20500_CR31","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1002\/humu.20880","volume":"29","author":"SE Plon","year":"2008","unstructured":"Plon, S. E. et al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum. Mutat. 29, 1282\u20131291. https:\/\/doi.org\/10.1002\/humu.20880 (2008).","journal-title":"Hum. Mutat."},{"key":"20500_CR32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13073-13019-10690-13072","volume":"12","author":"SE Brnich","year":"2019","unstructured":"Brnich, S. E. et al. Recommendations for application of the functional evidence PS3\/BS3 criterion using the ACMG\/AMP sequence variant interpretation framework. Genome Med. 12, 3. https:\/\/doi.org\/10.1186\/s13073-13019-10690-13072 (2019).","journal-title":"Genome Med."},{"key":"20500_CR33","doi-asserted-by":"publisher","first-page":"4880","DOI":"10.1158\/0008-5472.CAN-09-4563","volume":"70","author":"MS Lee","year":"2010","unstructured":"Lee, M. S. et al. Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays. Can. Res. 70, 4880\u20134890. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-4563 (2010).","journal-title":"Can. Res."},{"key":"20500_CR34","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41586-018-0461-z","volume":"562","author":"GM Findlay","year":"2018","unstructured":"Findlay, G. M. et al. Accurate classification of BRCA1 variants with saturation genome editing. Nature 562, 217\u2013222. https:\/\/doi.org\/10.1038\/s41586-018-0461-z (2018).","journal-title":"Nature"},{"key":"20500_CR35","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/1541-7786.MCR-17-0357","volume":"17","author":"A Petitalot","year":"2019","unstructured":"Petitalot, A. et al. Combining homologous recombination and phosphopeptide-binding data to predict the impact of BRCA1 BRCT variants on cancer risk. Mol. Cancer Res.: MCR 17, 54\u201369. https:\/\/doi.org\/10.1158\/1541-7786.MCR-17-0357 (2019).","journal-title":"Mol. Cancer Res.: MCR"},{"key":"20500_CR36","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1158\/2159-8290.CD-13-0094","volume":"3","author":"P Bouwman","year":"2013","unstructured":"Bouwman, P. et al. A high-throughput functional complementation assay for classification of BRCA1 missense variants. Cancer Discov. 3, 1142\u20131155. https:\/\/doi.org\/10.1158\/2159-8290.CD-13-0094 (2013).","journal-title":"Cancer Discov."},{"key":"20500_CR37","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1136\/jmg.2004.024711","volume":"42","author":"CM Phelan","year":"2005","unstructured":"Phelan, C. M. et al. Classification of BRCA1 missense variants of unknown clinical significance. J. Med. Genet. 42, 138\u2013146 (2005).","journal-title":"J. Med. Genet."},{"key":"20500_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mrfmmm.2008.09.017","volume":"660","author":"M Carvalho","year":"2009","unstructured":"Carvalho, M. et al. Analysis of a set of missense, frameshift, and in-frame deletion variants of BRCA1. Mutat. Res. 660, 1\u201311 (2009).","journal-title":"Mutat. Res."},{"key":"20500_CR39","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/hmg\/10.4.353","volume":"10","author":"J Vallon-Christersson","year":"2001","unstructured":"Vallon-Christersson, J. et al. Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families. Hum. Mol. Genet. 10, 353\u2013360 (2001).","journal-title":"Hum. Mol. Genet."},{"key":"20500_CR40","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.1021\/bi2003795","volume":"50","author":"N Coquelle","year":"2011","unstructured":"Coquelle, N., Green, R. & Glover, J. N. Impact of BRCA1 BRCT domain missense substitutions on phosphopeptide recognition. Biochemistry 50, 4579\u20134589. https:\/\/doi.org\/10.1021\/bi2003795 (2011).","journal-title":"Biochemistry"},{"key":"20500_CR41","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1074\/jbc.M210019200","volume":"278","author":"RS Williams","year":"2003","unstructured":"Williams, R. S. & Glover, J. N. Structural consequences of a cancer-causing BRCA1-BRCT missense mutation. J. Biol. Chem. 278, 2630\u20132635 (2003).","journal-title":"J. Biol. Chem."},{"key":"20500_CR42","doi-asserted-by":"publisher","first-page":"13595","DOI":"10.1073\/pnas.93.24.13595","volume":"93","author":"AN Monteiro","year":"1996","unstructured":"Monteiro, A. N., August, A. & Hanafusa, H. Evidence for a transcriptional activation function of BRCA1 C-terminal region. Proc. Natl. Acad. Sci. USA 93, 13595\u201313599 (1996).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"20500_CR43","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/382678a0","volume":"382","author":"MS Chapman","year":"1996","unstructured":"Chapman, M. S. & Verma, I. M. Transcriptional activation by BRCA1. Nature 382, 678\u2013679 (1996).","journal-title":"Nature"},{"key":"20500_CR44","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1093\/embo-reports\/kvd059","volume":"1","author":"G Nadeau","year":"2000","unstructured":"Nadeau, G. et al. BRCA1 can stimulate gene transcription by a unique mechanism. EMBO Rep. 1, 260\u2013265 (2000).","journal-title":"EMBO Rep."},{"key":"20500_CR45","doi-asserted-by":"publisher","first-page":"5605","DOI":"10.1073\/pnas.94.11.5605","volume":"94","author":"R Scully","year":"1997","unstructured":"Scully, R. et al. BRCA1 is a component of the RNA polymerase II holoenzyme. Proc. Natl. Acad. Sci. USA 94, 5605\u20135610 (1997).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"20500_CR46","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1093\/nar\/26.3.847","volume":"26","author":"AS Neish","year":"1998","unstructured":"Neish, A. S., Anderson, S. F., Schlegel, B. P., Wei, W. & Parvin, J. D. Factors associated with the mammalian RNA polymerase II holoenzyme. Nucl. Acids Res. 26, 847\u2013853 (1998).","journal-title":"Nucl. Acids Res."},{"key":"20500_CR47","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/mc.10148","volume":"38","author":"PL Cable","year":"2003","unstructured":"Cable, P. L. et al. Novel consensus DNA-binding sequence for BRCA1 protein complexes. Mol. Carcinog. 38, 85\u201396 (2003).","journal-title":"Mol. Carcinog."},{"key":"20500_CR48","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature11247","volume":"489","author":"I Dunham","year":"2012","unstructured":"Dunham, I. et al. An integrated encyclopedia of DNA elements in the human genome. Nature 489, 57\u201374. https:\/\/doi.org\/10.1038\/nature11247 (2012).","journal-title":"Nature"},{"key":"20500_CR49","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1002\/humu.22150","volume":"33","author":"GA Millot","year":"2012","unstructured":"Millot, G. A. et al. A guide for functional analysis of BRCA1 variants of uncertain significance. Hum. Mutat. 33, 1526\u20131537. https:\/\/doi.org\/10.1002\/humu.22150 (2012).","journal-title":"Hum. Mutat."},{"key":"20500_CR50","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40246-018-0183-1","volume":"12","author":"J Langerud","year":"2018","unstructured":"Langerud, J., Jarhelle, E., Van Ghelue, M., Ariansen, S. L. & Iversen, N. Trans-activation-based risk assessment of BRCA1 BRCT variants with unknown clinical significance. Hum Genomics 12, 51. https:\/\/doi.org\/10.1186\/s40246-018-0183-1 (2018).","journal-title":"Hum Genomics"},{"key":"20500_CR51","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/nprot.2015.136","volume":"11","author":"M Buckley","year":"2016","unstructured":"Buckley, M. et al. Enhancer scanning to locate regulatory regions in genomic loci. Nat. Protoc. 11, 46\u201360. https:\/\/doi.org\/10.1038\/nprot.2015.136 (2016).","journal-title":"Nat. Protoc."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-20500-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-20500-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-20500-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T13:30:06Z","timestamp":1664371806000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-20500-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,28]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["20500"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-20500-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,28]]},"assertion":[{"value":"16 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16203"}}